Core Viewpoint - Dian Diagnostics (300244) is expected to achieve a net profit attributable to shareholders of between 28 million and 42 million yuan in 2025, marking a turnaround from losses to profitability [2] Group 1: Financial Performance - The company anticipates a significant improvement in financial performance, with a projected net profit range of 28 million to 42 million yuan for 2025 [2] - Operating cash flow is expected to increase to approximately 1.8 billion yuan, indicating a positive trend in operational efficiency [2] Group 2: Strategic Focus - The company is focusing on enhancing operational quality by targeting high-value clients and strengthening the promotion of specialized tests and proprietary products [2] - There is a commitment to deepening regional integrated operations and solidifying market coverage, with a steady increase in the number of new clients [2] Group 3: Innovation and Technology - Dian Diagnostics is accelerating the commercialization of AI products, achieving breakthroughs in data operations, medical device registration, and overseas business expansion [2] - These advancements are expected to inject strong new momentum into the company's high-quality development [2]

证券日报网讯 1月26日，迪安诊断发布公告称，公司预计2025年度归属于上市公司股东的净利润盈利 2，800万元至4，200万元，上年同期亏损35，727.77万元。 （文章来源：证券日报） ...

（记者 王晓波） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经AI快讯，迪安诊断1月26日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润2800万元 ~4200万元，同比扭亏为盈。业绩变动主要原因是，2025年，公司正式启动新一轮五年战略规划，将战 略定位全面升级为"医学诊断智能解决方案引领者"，坚持以"AI+大数据"为技术引擎，积极构建融合"研 发生产、诊断服务、健康管理"于一体的健康诊疗数智化新生态。报告期内，公司以提升经营质量为核 心，聚焦高价值客户，强化特检与自有产品推广，深化区域一体化运营，持续夯实存量市场的覆盖优 势，新签客户数稳步增加，经营性现金流净额提升至约18亿元，经营效益趋势逐渐向好；在创新与技术 驱动方面，公司加快AI产品的商业化进程，在数据运营与交易、获取三类医疗器械注册证、海外业务 拓展等领域取得突破性进展，为公司高质量发展注入强劲新动能。 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 ...

南财智讯1月26日电，迪安诊断发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 2800万元—4200万元，预计同比扭亏；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利 润为1000万元—1500万元。业绩变动原因说明：1、2025年，公司正式启动新一轮五年战略规划，将战 略定位全面升级为"医学诊断智能解决方案引领者"，坚持以"AI+大数据"为技术引擎，积极构建融合"研 发生产、诊断服务、健康管理"于一体的健康诊疗数智化新生态。报告期内，公司以提升经营质量为核 心，聚焦高价值客户，强化特检与自有产品推广，深化区域一体化运营，持续夯实存量市场的覆盖优 势，新签客户数稳步增加，经营性现金流净额提升至约18亿元，经营效益趋势逐渐向好；在创新与技术 驱动方面，公司加快AI产品的商业化进程，在数据运营与交易、获取三类医疗器械注册证、海外业务 拓展等领域取得突破性进展，为公司高质量发展注入强劲新动能。2、报告期内，面临医院端需求增速 放缓、集采与拆套餐等多重挑战，公司短期营收承压，利润空间收窄。为把握行业资源整合的窗口期， 公司通过区域组织优化与中后台共享机制建设，着力打造区域一体化运营能力 ...

Core Viewpoint - The company expects a net profit of 28 million to 42 million yuan for the year 2025, a significant recovery from a loss of 357 million yuan in the same period last year [1] Group 1: Strategic Planning - The company will officially launch a new five-year strategic plan in 2025, upgrading its strategic positioning to become a "leader in intelligent medical diagnostic solutions" [1] - The company will focus on "AI + big data" as its technological engine, aiming to build an integrated health diagnostic ecosystem that combines research and development, diagnostic services, and health management [1] Group 2: Operational Performance - The company aims to enhance operational quality by focusing on high-value clients, strengthening the promotion of specialized tests and proprietary products, and deepening regional integrated operations [1] - The number of new clients signed has steadily increased, and the net operating cash flow has improved to approximately 1.8 billion yuan, indicating a positive trend in operational efficiency [1] Group 3: Innovation and Technology - The company is accelerating the commercialization of AI products and has made breakthroughs in data operations and transactions, obtaining registration certificates for three types of medical devices, and expanding overseas business [1] - These advancements are expected to inject strong new momentum into the company's high-quality development [1]

证券代码：300244 证券简称：迪安诊断 公告编号：2026-004 迪安诊断技术集团股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 本次业绩预告相关财务数据未经注册会计师审计。 三、业绩变动原因说明 1、2025 年，公司正式启动新一轮五年战略规划，将战略定位全面升级为"医 学诊断智能解决方案引领者"，坚持以"AI+大数据"为技术引擎，积极构建融合"研 发生产、诊断服务、健康管理"于一体的健康诊疗数智化新生态。报告期内，公 司以提升经营质量为核心，聚焦高价值客户，强化特检与自有产品推广，深化区 域一体化运营，持续夯实存量市场的覆盖优势，新签客户数稳步增加，经营性现 金流净额提升至约 18 亿元，经营效益趋势逐渐向好；在创新与技术驱动方面， 公司加快 AI 产品的商业化进程，在数据运营与交易、获取三类医疗器械注册证、 （一）业绩预告期间 2025 年 01 月 01 日—2025 年 12 月 31 日 （二）业绩预告情况 1、预计净利润为正值且属于扭亏为盈情形 2、以区间数进行业绩预告的： | 项 ...

Core Viewpoint - The medical services sector experienced a rise of 1.19% on January 23, with notable gains from companies like Nuohua Zhiyuan, which led the sector's performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1]. - The medical services sector saw significant individual stock movements, with Nuohua Zhiyuan (688315) closing at 17.00, up 13.26%, and Hai Te Biological (300683) closing at 33.31, up 7.66% [1]. Group 2: Trading Volume and Value - Nuohua Zhiyuan had a trading volume of 219,500 shares and a transaction value of 365 million yuan [1]. - Hai Te Biological recorded a trading volume of 190,900 shares with a transaction value of 632 million yuan [1]. Group 3: Capital Flow - The medical services sector saw a net inflow of 999.1 million yuan from institutional investors, while retail investors experienced a net outflow of 1.069 billion yuan [2]. - The capital flow data indicates that major stocks like Diyan Diagnosis (300244) had a net inflow of 288 million yuan from institutional investors [3].

Group 1 - The A-share market has seen a continued rise in certain AIGC concept stocks, indicating positive market sentiment towards this sector [1] - Zhejiang Wenhu Internet has reached its daily limit increase, showcasing strong investor interest [1] - Century Tianhong has increased by over 7%, reflecting robust performance among AIGC-related companies [1] Group 2 - Other notable gainers include Guangyun Technology, Chaotu Software, Dian Diagnostics, and Qianfang Technology, all rising by more than 5% [1] - Companies such as Jiuzhoutong, Danghong Technology, Leizhi Group, Fushi Holdings, Keda Guochuang, Yanshan Technology, and Zhongkong Technology have all seen increases of over 4% [1]

Group 1 - A-share market sees a rise in AIGC concept stocks, with notable increases in several companies [1] - Zhejiang Wenhu Internet (浙文互联) hits the daily limit with a 10.05% increase, while Century Tianhong (世纪天鸿) rises by 7.63% [2] - Other companies such as Guangyun Technology (光云科技), SuperMap Software (超图软件), and Di'an Diagnostics (迪安诊断) also experience significant gains, exceeding 5% [1][2] Group 2 - The total market capitalization of Zhejiang Wenhu Internet is 17.9 billion, with a year-to-date increase of 54.09% [2] - Century Tianhong has a market cap of 4.236 billion and a year-to-date increase of 16.75% [2] - Guangyun Technology's market cap stands at 11.3 billion, with a year-to-date increase of 57.32% [2]

证券之星消息，1月21日，生物经济（970038）指数报收于2249.37点，涨0.3%，成交272.77亿元，换手 率2.27%。当日该指数成份股中，上涨的有28家，迪安诊断以5.59%的涨幅领涨，下跌的有22家，康弘药 业以1.78%的跌幅领跌。 生物经济（970038）指数十大成份股详情如下： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 000021 | 深科技 | 1.87亿 ﮯ | 3.06% | -9441.13万 | -1.55% | -9272.83万 | -1.52% | | 300142 | 沃森生物 | 6444.78万 | 8.62% | -3115.26万 | -4.16% | -3329.52万 | -4.45% | | 000930 | 中粮科技 | 5427.62万 | 9.84% | 491.65万 | 4 0.89% | -5919.27万 | -10.73% | | 002 ...